1 / 5

A5142 Study Design

A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142.

zaynah
Download Presentation

A5142 Study Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A., Haubrich R., DiRienzo G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Havlir D., Mellors J.W., AIDS Clinical Trials Group 5142 Study Team

  2. A5142 Study Design Primary endpoints* • Time from randomization to virologic failure (VF) • VF: 2 consecutive HIV-1 RNA measurements > 200 c/mL after week 32 • Time from randomization to regimen completion • VF OR treatment-limiting toxicityor intolerance, as assessed by the site investigator to any regimen component LPV/r SGC 400/100 mg BID + 3TC + d4T XR or TDF or ZDV LPV/r 533/133 mg BID + EFV 600 mg QD Multicenter Randomized Open-label LPV/r SGC 533/133 mg BID + EFV 600 mg QD 96 weeks Screening ARV-naïve HIV RNA >2,000 c/mL Any CD4 count EFV 600 mg QD+ 3TC + d4T XR or TDF or ZDV • Stratification by: • HIV RNA > 100,000 copies/mL • Hepatitis infection • Selection of d4T, TDF or ZDV N  250/arm * Multiple between-arm comparisons and interim analyses  Adjusted significance level = 0.016 Riddler SA, Haubrich R et al., XVI IAC, Toronto 2006, #THLB0204

  3. 753 subjects NRTI selection (prior to randomization) ZDV 42% D4T XR 24% TDF 34% median follow up 112 weeks median CD4 182 cells/mm3 median HIV-1 RNA 100,000 copies/mL No differences between arms in baseline characteristics A5142 Primary Results Riddler SA, Haubrich R et al., XVI IAC, Toronto 2006, #THLB0204

  4. A5142 Primary Results * LPV vs EFV- other comparisons ns; ** did not meet significance threshold of 0.016; *** EFV vs both LPV arms Riddler SA, Haubrich R et al., XVI IAC, Toronto 2006, #THLB0204

  5. Other Key Findings • No difference in time to treatment limiting toxicity between groups • Preliminary analysis of 124 of 227 subjects with virologic failure (additional samples being analyzed) • Preliminary resistance analyses show a trend toward more NNRTI resistance in the LPV/EFV arm compared with EFV + 2 NRTI. • Resistance mutations in 2 drug classes (M184I/V + K103N) were more common in the EFV + 2 NRTI arm. PI mutations were not found in the LPV + 2 NRTI arm. Riddler SA, Haubrich R et al., XVI IAC, Toronto 2006, #THLB0204

More Related